Based on the characteristics of individuals (genomic data, information on lifestyle, etc.) personalised medicine aims to improve the efficiency of diagnostics, treatments and preventive measures, for the benefit of patients and citizens. What are the challenges and the existing solutions for its implementation? This key question is at the heart of the virtual conference organised on February 25-26, 2021 by ICPerMed, with the support of the European Commission and the French National Research Agency (ANR).
Personalised medicine: the next generation medicine by 2030
ICPerMed, the international consortium on personalised medicine, bringing together more than 45 European and international partners, has analysed the needs of stakeholders in the field over recent years and identified five main challenges and levers of action for the implementation of personalised medicine. These are detailed in a Vision Paper published in 2019.
Based on this strategic document, the ICPerMed “Personalised Medicine - From Vision to Practice” conference is structured around five sessions during which speakers present courses of action for:
- Health democracy and the inclusion of patients' and citizens' preferences;
- Strengthening data harmonisation for better use;
- Integration of personalised medicine into health systems;
- Creation of an efficient entrepreneurial ecosystem between academy and industry in order to stimulate innovation in health;
- Redefining the notion of value in healthcare by incorporating patient preferences and socio-economic aspects.
A session is also dedicated to lessons learned from the COVID-19 pandemic and the contribution of personalised medicine in the fight against the disease. Furthermore, ICPerMed features and honours best practices in personalised medicine research through the ICPerMed Recognition 2020, aiming to recognise, encourage, promote and disseminate outstanding examples.
The conference brings together world-renowned researchers, experts in ELSA (ethical, legal and social aspects), health economists, patients and representatives from industry, regulatory authorities, and members of ICPerMed, including representatives of ministries, research funding agencies and policy makers.